Vtv Therapeutics INC Form 4 insider transactions

Baker Bros. Advisors LP, through its associated entities and individuals, has acquired 6,000 non-qualified stock options for vTv Therapeutics Inc. (VTVT) as part of director compensation.

Daniel K. Spiegelman, a Director at VTV Therapeutics Inc., acquired stock options for 6,000 shares of Class A Common Stock.

A VTVT director acquired stock options, indicating a potential long-term commitment to the company's performance.

Fahed Al-Marzooqi, a director at vTv Therapeutics Inc., acquired stock options granting the right to buy 6,000 shares.

Anne M. Phillips, a Director at vTv Therapeutics Inc., acquired stock options for 6,000 shares.

Srinivas Akkaraju, a director of vTv Therapeutics Inc., reported significant acquisitions of common stock and warrants through affiliated funds.

VTVT Director Srinivas Akkaraju, through Samsara BioCapital, L.P., reported the acquisition of pre-funded and common warrants for over 1.3 million shares of Class A Common Stock.

Baker Bros. Advisors-managed funds acquired significant equity and warrant positions in vTv Therapeutics through a private placement, increasing their beneficial ownership.

Entities affiliated with Baker Bros. Advisors LP, including key principals, have reported the grant of 4,000 non-qualified stock options to Dr. Raymond Cheong, a director of vTv Therapeutics Inc., as part of his compensation.

vTv Therapeutics Inc. Director Daniel K. Spiegelman was granted 4,000 stock options with an exercise price of $16.59, which will vest by June 2026.

A director at vTv Therapeutics Inc. was granted 4,000 stock options with an exercise price of $16.59, vesting by June 2026.

vTv Therapeutics Inc. Director Anne M. Phillips was granted 4,000 stock options with an exercise price of $16.59, vesting by June 2026.

Fahed Al-Marzooqi, a Director at vTv Therapeutics Inc., was granted 4,000 stock options with an exercise price of $16.59 per share, vesting by June 2026.

Michael Stephen Tung, EVP & CFO of vTv Therapeutics Inc., acquired 45,000 employee stock options on May 19, 2025, at an exercise price of $21.25.

Srinivas Akkaraju, a director at vTv Therapeutics, acquired stock options on June 25, 2024, according to a recent SEC Form 4 filing.

Paul J. Sekhri, CEO of VTV Therapeutics, reports the acquisition of 108,000 employee stock options.

Samsara BioCapital, a major shareholder of VTV Therapeutics, exchanged 58,836 shares of Class A Common Stock for pre-funded warrants exercisable for 58,885 shares at $0.01 per share.

A VTV Therapeutics director, Srinivas Akkaraju, through Samsara BioCapital, L.P., exchanged 58,836 shares of Class A Common Stock for pre-funded warrants exercisable for 58,885 shares at $0.01 per share.

VTV Therapeutics' CEO, Paul Sekhri, purchased a total of 5,000 shares of Class A Common Stock through a pre-arranged 10b5-1 trading plan.

Baker Bros. Advisors LP reports the grant of non-qualified stock options to Dr. Raymond Cheong, a director of vTv Therapeutics Inc., on June 25, 2024.

Director Daniel K. Spiegelman acquired stock options in VTV Therapeutics Inc. on June 25, 2024.

Director Fahed Al-Marzooqi of vTv Therapeutics Inc. acquired stock options on June 25, 2024.

Director Anne M. Phillips reports the acquisition of stock options in VTV Therapeutics Inc.

Director Srinivas Akkaraju of vTv Therapeutics Inc. reports acquisition of stock options.

Director Fahed Al-Marzooqi acquired stock options in VTV Therapeutics Inc. on February 27, 2024, which were later approved by shareholders on June 11, 2024.

VTV Therapeutics CEO Paul Sekhri was granted stock options for 89,212 shares on February 27, 2024, vesting quarterly over three years, contingent on shareholder approval of the 2024 Equity Incentive Plan.

Steven L. Tuch, CFO of vTv Therapeutics Inc., reports the acquisition of employee stock options.

Director Anne M. Phillips acquired stock options in VTV Therapeutics Inc. following shareholder approval of the 2024 Equity Incentive Plan.

vTv Therapeutics Inc. executed an exchange agreement with Baker Bros. funds, swapping common stock for prefunded warrants.

Srinivas Akkaraju, a director and 10% owner of vTv Therapeutics Inc., reports acquiring Class A Common Stock and Pre-Funded Warrants.